Paravertebral blocks and enhanced recovery after surgery protocols in breast reconstructive surgery: patient selection and perspectives

Rajiv P Parikh
Terence M Myckatyn
Department of Surgery, Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, St Louis, MO, USA

Abstract: The management of postoperative pain is of critical importance for women undergoing breast reconstruction after surgical treatment for breast cancer. Mitigating postoperative pain can improve health-related quality of life, reduce health care resource utilization and costs, and minimize perioperative opiate use. Multimodal analgesia pain management strategies with nonopioid analgesics have improved the value of surgical care in patients undergoing various operations but have only recently been reported in reconstructive breast surgery. Regional anesthesia techniques, with paravertebral blocks (PVBs) and transversus abdominis plane (TAP) blocks, and enhanced recovery after surgery (ERAS) pathways have been increasingly utilized in opioid-sparing multimodal analgesia protocols for women undergoing breast reconstruction. The objectives of this review are to 1) comprehensively review regional anesthesia techniques in breast reconstruction, 2) outline important components of ERAS protocols in breast reconstruction, and 3) provide evidence-based recommendations regarding each intervention included in these protocols. The authors searched across six databases to identify relevant articles. For each perioperative intervention included in the ERAS protocols, the literature was exhaustively reviewed and evidence-based recommendations were generated using the Grading of Recommendations, Assessment, Development, and Evaluation system methodology. This study provides a comprehensive evidence-based review of interventions to optimize perioperative care and postoperative pain control in breast reconstruction. Incorporating evidence-based interventions into future ERAS protocols is essential to ensure high value care in breast reconstruction.

Keywords: enhanced recovery after surgery, ERAS, postmastectomy breast reconstruction, autologous flap, breast implant

Introduction
Breast reconstruction after surgical treatment for breast cancer has the potential to significantly improve patients’ health-related quality of life.1–7 Although most women report greater satisfaction with appearance and improved physical, psychosocial, and sexual well-being following breast reconstruction, the management of postoperative pain remains challenging. Inadequate postoperative pain control contributes to unnecessary health care resource utilization while exacerbating costs and hindering patient recovery. This is true for both implant-based (prosthetic) and microvascular (autologous) breast reconstruction techniques. Nearly one-half of patients undergoing breast reconstruction experience postoperative pain syndromes.8,9 Inadequately controlled acute postoperative pain is associated with an increased likelihood of developing persistent postsurgical pain, which reduces the quality of life.8–12 Additionally, poorly controlled pain may result in a prolonged opioid dependency, contributing to the ongoing opioid epidemic in the
Recently, there have been a few interventions introduced that have promise in optimizing pain control and postoperative recovery for women with breast cancer undergoing breast reconstruction. The most prevalent of these are regional anesthesia techniques, including paravertebral blocks (PVBs) and transversus abdominis plane (TAP) blocks, and evidence-based multimodal perioperative management approaches, referred to as Enhanced Recovery after Surgery (ERAS) protocols. The purported strengths of these interventions are that they significantly improve the value of surgical care by enhancing postoperative recovery.23–27 ERAS protocols utilize evidence-based recommendations to standardize perioperative care.28 Although widely adopted in various surgical disciplines, there was minimal literature on opioid-sparing multimodal analgesia strategies in reconstructive breast surgery until recently.29 As a result, perioperative approaches have traditionally been based on individual experience and differed tremendously across institutions, potentially contributing to variations in system-wide quality and unnecessary resource utilization. Therefore, the goals of this article are to 1) comprehensively review regional anesthesia techniques in breast reconstruction, 2) outline important components of ERAS protocols in breast reconstruction, and 3) provide evidence-based recommendations regarding all perioperative interventions aimed at enhancing recovery in breast reconstruction.

Methods
This study was conducted in the following two stages: 1) comprehensive review of regional analgesic techniques and ERAS protocols in breast reconstruction and 2) literature review and generation of evidence-based recommendations for all interventions included in ERAS protocols for breast reconstruction. The authors followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines throughout this investigation.30,31

Review of regional analgesic techniques and ERAS protocols in breast reconstruction
To identify regional analgesia and ERAS protocols, we searched the Ovid MEDLINE, EMBASE, SCOPUS, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases from January 1990 through October 2017 using strategies designed by a medical librarian for the concepts of breast reconstruction, regional analgesia, perioperative care or fast track or enhanced recovery, and LOS, postoperative complications, or pain. All results were exported to EndNote, and duplicate citations were removed. References were then hand-searched, and relevant articles were retrieved. All studies reporting patients undergoing breast reconstruction in an ERAS protocol or with regional analgesia techniques were eligible for inclusion. Articles in all languages were considered. A study was excluded if full text could not be obtained.

Evidence-based recommendations for ERAS protocol items
In the second stage, we performed a literature review of each intervention included in the previously identified ERAS protocols with search parameters for [X] and breast reconstruction, where X = specific intervention in the ERAS protocol. For each item, searches were performed to identify the best available evidence, with priority given to meta-analyses, systematic reviews, and randomized-controlled trials (RCTs). In the absence of high-quality evidence specific to breast reconstruction, we included nonrandomized observational studies and/or extrapolated evidence from the surgical literature. Consistent with other studies, we used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to appraise the overall quality of evidence for each intervention and to assign a level of strength to each recommendation.32–36 The GRADE system is widely adopted, and the preferred methodology of The Cochrane Collaboration and the Agency for Healthcare Research and Quality (AHRQ) for grading clinical evidence and developing recommendations for clinical practice is used.37 The GRADE approach classifies recommendations into two levels, such as strong (Grade 1) and weak (Grade 2), and then subclassifies each grade into three categories based on the quality of evidence (A = high quality, B = moderate quality, and C = low quality).38–40 The strength of recommendation is primarily influenced by the tradeoff between the benefits, risks, and burdens of an intervention and by the quality of the evidence available.

Regional analgesic techniques in breast reconstruction
Regional anesthesia techniques are utilized across surgical disciplines and have demonstrated efficacy at reducing both
acute and chronic postoperative pain, opiate use, and LOS for various surgical procedures. In reconstructive breast surgery, the two most common techniques for regional anesthesia are PVBs and TAP blocks. PVBs are utilized in both prosthetic and autologous breast reconstruction procedures, whereas TAP blocks only have utility in abdominally based autologous breast reconstruction procedures such as deep inferior epigastric artery perforator (DIEP) flaps and transverse rectus abdominis myocutaneous (TRAM) flaps. Traditionally, regional blocks or infusions were performed with bupivacaine, which has a duration of action between 8 and 12 hours. However, recently, several groups have shifted toward using liposomal bupivacaine, which has a duration of action ranging from 72 to 96 hours. Although comparative studies evaluating cost and outcomes between bupivacaine and liposomal bupivacaine are still needed, there is preliminary evidence to demonstrate the efficacy and merit the use of liposomal bupivacaine in reconstructive breast surgery.

**TAP blocks**

TAP blocks were initially introduced in the literature in the early 2000s and have subsequently gained widespread acceptance as an effective technique for regional anesthesia in various abdominally based surgical operations. In abdominally based autologous breast reconstruction procedures, TAP blocks were first reported as having efficacy for improving pain control and reducing opiate requirements by Hivelin et al in 2011. To date, there is evidence from one RCT, two prospective cohort studies, and two retrospective studies demonstrating that TAP blocks are safe and significantly reduce postoperative opioid use in abdominally based autologous breast reconstruction. There are several excellent articles that detail the relevant anatomy and technical components of performing a TAP block. Briefly, TAP blocks involve anesthetizing the sensory innervation to the anterior abdominal wall, which is traditionally considered to be derived from the T6-L1 nerves from the anterior rami of the thoracolumbar spinal nerves. The lumbar triangle of Petit is often used as the primary landmark to localize the injection to the plane between the internal oblique musculature and the transversus abdominis musculature. In autologous breast reconstruction, this block is performed under direct visualization following flap harvest and prior to closure of the abdominal donor site. A blunt tip injection cannula is inserted into the TAP and local anesthetic in the form of bupivacaine or liposomal bupivacaine is injected. Alternatively, a catheter can also be introduced in the plane and redosed periodically in the perioperative period. For bilateral procedures, bilateral blocks are performed.

**PVBs**

There is considerable evidence supporting the use of PVBs in breast surgery. In a meta-analysis of 15 RCTs in breast cancer surgery, PVBs were determined to be effective at reducing postoperative pain and hospital LOS. In reconstructive breast surgery, there is literature to support the use of PVBs in both prosthetic breast reconstruction and autologous breast reconstruction procedures. A recent prospective study by Parikh et al demonstrated a significant reduction in postoperative pain and LOS for women with breast cancer undergoing mastectomy abdominally based autologous breast reconstruction with a PVB compared to women who did not receive a PVB. In a follow-up study from the same group, the authors also reported a reduction in opiate medication requirements for patients undergoing autologous breast reconstruction with use of a PVB compared to patients undergoing autologous breast reconstruction without a PVB. Of importance, the use of PVBs did not compromise intraoperative perfusion or change fluid requirements in this cohort. The value of PVBs is not confined to abdominally based breast reconstruction. In 2016, Unkart et al reported their experience with PVBs for patients undergoing breast reconstruction with latissimus dorsi autologous flaps. In prosthetic breast reconstruction, there are several retrospective cohort studies and one RCT that similarly confirm the value of PVBs versus general anesthesia alone. Coopey et al and Fahy et al independently demonstrated reductions in LOS, perioperative opiate use, and postoperative pain for patients undergoing immediate prosthetic breast reconstruction with a PVB compared to patients who did not receive a PVB. This reduction in perioperative opiate use was subsequently confirmed in a 2015 report by Glissmeyer et al, where the authors reported that morphine equivalents were significantly lower in the cohort of patients who received a PVB in postmastectomy breast reconstruction compared to the cohort of patients who did not. In 2016, Wolf et al reported results from the first prospective RCT of PVBs in prosthetic breast reconstruction. In a total of 74 patients (35 who received a PVB and 34 in the control group), the authors demonstrated that patients who received a PVB, compared to patients who did not, required significantly less opiates intraoperatively and postoperatively, had lower pain scores postoperatively, and required less antiemetic medications perioperatively. These procedures can be performed with consistency and...
with minimal risk for complications, as confirmed in a 2016 report of 856 patients undergoing 1427 PVBs for regional anesthesia in postmastectomy prosthetic reconstructive breast surgery procedures where the complication rate was <1.0%. Similar to TAP blocks, there are excellent articles that detail the anatomical and technical considerations for performing PVBs. Briefly, our preferred approach is to inject 15–20 mL of 0.5% bupivacaine (bilateral for bilateral procedures) at the T2–T4 paravertebral spaces under ultrasound guidance in the immediate preoperative setting. These procedures are performed by fellowship trained anesthesiologists on a dedicated regional block team.

Recommendation: There is moderate-quality evidence to support the inclusion of regional analgesic techniques with TAP blocks and PVBs in ERAS protocols for microvascular breast reconstruction and PVBs for prosthetic breast reconstruction (Grade 1B).

**ERAS protocols in breast reconstruction**

Following review, there were five nonrandomized studies from four different institutions that evaluated ERAS protocols in breast reconstruction (Table 1). In total, studies evaluated 49 patients undergoing prosthetic reconstruction and 661 participants in ERAS protocols vs. usual care protocols.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Location</th>
<th>Year</th>
<th>Methods</th>
<th>Participants in ERAS protocol, n</th>
<th>Participants in usual care protocol, n</th>
<th>Perioperative interventions included in ERAS protocol</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batdorf et al</td>
<td>USA</td>
<td>2015</td>
<td>Retrospective cohort</td>
<td>49</td>
<td>51</td>
<td>Preoperative education; fasting only 2 hours for clear liquids prior to surgery; antimicrobial prophylaxis; multimodal analgesia with opiates, NSAIDs, acetaminophen, gabapentin + TAP blocks with liposomal bupivacaine; euvolemia fluid management; antiemetics; oral feeding on POD 0; early ambulation; urinary catheter removal POD 1</td>
<td>Length of stay, total opiate use, pain scores, flap loss, systemic complications, surgical complications</td>
</tr>
<tr>
<td>Bonde et al</td>
<td>Denmark</td>
<td>2015</td>
<td>Case–control</td>
<td>177</td>
<td>277</td>
<td>Preoperative education; antimicrobial prophylaxis; multimodal analgesia with opiates (on request), NSAIDs and acetaminophen; early ambulation; urinary catheter removal POD 1</td>
<td>Length of stay, surgical complications, flap loss</td>
</tr>
<tr>
<td>Bonde et al</td>
<td>Denmark</td>
<td>2016</td>
<td>Retrospective cohort</td>
<td>16</td>
<td>N/A</td>
<td>Preoperative education; antimicrobial prophylaxis; multimodal analgesia with opiates (on request), NSAIDs, acetaminophen, and gabapentin; minimally invasive approach (DIEP flaps only); oral feeding on POD 1; early ambulation; urinary catheter removal POD 1</td>
<td>Length of stay, surgical complications, flap loss</td>
</tr>
<tr>
<td>Afonso et al</td>
<td>USA</td>
<td>2017</td>
<td>Retrospective cohort</td>
<td>42</td>
<td>49</td>
<td>Preoperative education; fasting only 2 hours for clear liquids prior to surgery; multimodal analgesia with opiates, NSAIDs (IV ketorolac), and acetaminophen + TAP blocks with liposomal bupivacaine; goal-directed fluid management; antiemetics; oral feeding on POD 1; early ambulation; urinary catheter removal POD 1</td>
<td>Length of stay, total opiate use, pain scores, flap loss, systemic complications, surgical complications</td>
</tr>
<tr>
<td>Dumestre et al</td>
<td>Canada</td>
<td>2017</td>
<td>Retrospective cohort</td>
<td>29</td>
<td>29</td>
<td>Preoperative education; fasting only 3 hours for clear liquids prior to surgery; multimodal analgesia with opiates, celecoxib/NSAIDs, and acetaminophen + local nerve blocks with bupivacaine</td>
<td>Length of stay, QoR scores, pain scores, systemic complications, surgical complications</td>
</tr>
</tbody>
</table>

**Abbreviations:** DIEP, deep inferior epigastric artery perforator; ERAS, enhanced recovery after surgery; NSAIDs, nonsteroidal anti-inflammatory drugs; POD, postoperative day; QoR, quality of recovery; TAP, transversus abdominis plane; N/A, not available.
patients undergoing 783 microvascular flaps for autologous reconstruction. Of them, 29 patients undergoing prosthetic reconstruction and 284 patients undergoing 345 flaps were treated in an ERAS protocol, whereas 29 patients undergoing prosthetic reconstruction and 377 patients undergoing 438 flaps were treated with conventional care. There were two studies from the same group: the first study, published in 2015, compared an ERAS protocol with conventional care and the second study, published in 2016, reported on 16 patients in a modified ERAS protocol, which was then compared with their previously published data on patients in the first version of the ERAS protocol. There was substantial heterogeneity between the treatment protocols, patient groups, comorbidities reported, and postoperative outcomes measured; therefore, quantitative analyses across studies were not feasible. In regard to outcomes reported, all studies reported LOS, but only three studies reported postoperative pain scores, two studies reported opiate use, and three studies reported systemic complications. No study reported cost outcomes. Additionally, data on relevant covariates or potential confounders were inconsistently reported.

**Evidence-based recommendations for components of ERAS protocols**

**Preoperative interventions**

**Patient education/counseling**

Preoperative patient education and counseling are essential to patient-centered care, one of the key domains of high-quality health care. Patient education and counseling should address patients’ expectations, include a comprehensive discussion of the risks and benefits of different treatment options, assess patients’ understanding of their expected perioperative course, and involve patients in the decision-making process. In breast reconstruction, several studies, utilizing the BREAST-Q patient-reported outcome measure, have shown a positive association between patient’s satisfaction with preoperative information and postoperative outcome. Additionally, Sheehan et al and Zhong et al independently demonstrated that lower satisfaction with preparatory information is associated with an increased likelihood of regret following breast reconstruction. When expanded across surgical specialties, there is also evidence that preoperative education is an independent predictor of reduced LOS in ERAS protocols.

Recommendation: Preoperative education is integral to patient-centered care and has the potential to improve postoperative patient-reported outcomes while minimizing decision regret. The impact of patient education on LOS has not been examined in breast reconstruction; however, there are minimal risks associated with this intervention. Consequently, we strongly recommend ERAS protocols in breast reconstruction that incorporated preoperative education and counseling, ideally in a shared decision-making model (Grade 1B).

**Fasting, nutrition, and carbohydrate loading**

In two of the ERAS protocols for breast reconstruction, preoperative fasting from the intake of clear liquids for at least 2 hours prior to surgery was included in the treatment pathway, whereas one study recommended at least 3 hours of fasting. For decades, preoperative fasting was recommended with “NPO after midnight” in an effort to minimize the risk of pulmonary aspiration by decreasing gastric volume. However, over the last several years, this dogma has been challenged by a multitude of studies demonstrating preoperative fasting from the intake of clear fluids for 2 hours and from the intake of solids for 6 hours to be optimal. A 2017 meta-analysis of RCTs demonstrated a lower risk of aspiration for patients with clear liquid intake up to 2 hours prior to surgery versus traditional fasting (>4 hours). Furthermore, prior systematic reviews concluded that preoperative fasting to 6 hours for solids is safe. The primary concern with prolonged fasting is exacerbation of the surgical stress response, which constitutes a coordinated reaction to surgical injury. Ultimately, prolonged catabolism from fasting combined with the surgical stress response can potentiate hyperglycemia, insulin resistance, hyperthermia, immunosuppression, and muscle loss in the perioperative period, potentially contributing to adverse outcomes and delayed recovery. Therefore, the goal with perioperative nutritional management is to mitigate these effects.

In addition to changing fasting guidelines, there is considerable evidence from meta-analyses, systematic reviews, and RCTs demonstrating the intake of carbohydrate-rich liquids, ie, carbohydrate loading, prior to elective surgery, reduces postoperative insulin resistance and hyperglycemia, minimizes muscle loss, and shortens LOS. Furthermore, several RCTs establish clear liquid intake and carbohydrate loading up to 2 hours before a procedure improves patients’ subjective well-being by reducing thirst and hunger. Although there are no specific studies in breast reconstruction, evidence-based recommendations can be adapted from these studies in the elective surgical population.

Recommendation: We recommend minimizing preoperative fasting to only 2 hours for clear liquids and 6 hours for solids (Grade 1A). Furthermore, we recommend preoperative
carbohydrate loading via oral liquid intake up to 2 hours prior to surgery to mitigate adverse effects associated with the surgical stress response (Grade 1A).

**Antimicrobial prophylaxis**

All ERAS protocols included preoperative antibiotic use. In breast reconstruction, evidence for perioperative antibiotics for the prevention of surgical site infection (SSI) is largely based on studies in the prosthetic population; data on antibiotic use in microvascular breast reconstruction are limited. A prior survey of members of the American Society for Reconstructive Microsurgery (ASRM) revealed consensus agreement regarding preoperative administration of antibiotics within 1 hour prior to microvascular breast reconstruction; however, no consensus was present on the optimal duration of antibiotic administration.92 The practice of administering preoperative antibiotics within 60 minutes of incision is supported by considerable high-quality evidence, albeit not specific to breast reconstruction, including a 2014 Cochrane review of RCTs, and recommended by major national organizations, including Centers for Disease Control and Prevention (CDC), the Surgical Care Improvement Project (SCIP), and the AHRQ.93–97 What is less clear is the optimal duration of antibiotics. SCIP and CDC guidelines recommend a short duration (<24 hours) of prophylaxis.94,95,97 There are two retrospective studies comparing patients receiving 24 versus >24 hours of antimicrobial prophylaxis in microvascular breast reconstruction.98,99 These studies showed no reduction in overall incidence of SSI for patients receiving antibiotics >24 hours. This is also supported by systematic reviews regarding the duration of prophylactic antibiotic use in prosthetic breast reconstruction, which presumably has an equal or higher intrinsic risk of SSI due to the placement of an implant.100,101

One of the ERAS protocols included antiseptic bathing for antimicrobial prophylaxis. Preoperative bathing and postoperative bathing with skin antiseptics are often recommended in procedures involving the placement of a prosthesis; however, the prevalence of this practice is unclear.102–104 A 2015 Cochrane review and a 2017 meta-analysis separately confirmed that there is no clear evidence of benefit for showering/bathing with antiseptic solution compared to usual wash products prior to clean surgeries.105,106

Recommendation: All patients undergoing breast reconstruction should receive preoperative antibiotics within 1 hour of incision. There is no documented benefit to prolonged antimicrobial prophylaxis; therefore, we recommend adherence to SCIP and CDC guidelines for administering only 24 hours of antibiotics (Grade 1A). There is no proven benefit for preoperative showering/bathing with antiseptic solution; thus, we recommend patients follow usual bathing practices prior to surgery (Grade 1A).

**Intraoperative management**

**Preemptive analgesia and PVBs**

The management of postoperative pain with multimodal therapy is a key component of ERAS protocols. Multimodal protocols are presumed to be effective because they address different pain mechanisms to reduce acute postoperative pain, which may subsequently blunt the development of chronic pain.27,107 ERAS protocols for breast reconstruction incorporated preemptive analgesia with opioid (at the discretion of the anesthesia provider) and nonopioid combinations of regional anesthesia blocks (2/5 studies), nonsteroidal anti-inflammatory drugs (NSAIDs) (4/5 studies), acetaminophen (5/5 studies), and/or gabapentin (4/5 studies). Regional anesthesia techniques were previously discussed; NSAIDs, acetaminophen, and gabapentin are discussed in the postoperative management section. Local anesthetic techniques utilizing continuous infusion pain catheters and regional anesthetic techniques utilizing peripheral nerve blocks are described in the literature. A meta-analysis in 2013 demonstrated local anesthetic pain catheters at the donor site, either on top of the rectus sheath or under the rectus fascia, significantly decreased opioid use but only showed a trend toward reducing LOS, for patients undergoing microvascular breast reconstruction (MBR).108 Furthermore, two RCTs confirmed that continuous infusion catheters have no deleterious effect on flap perfusion or complications.109,110

Recommendation: There is moderate quality evidence to support the inclusion of local anesthetic techniques and preemptive analgesia in breast reconstruction (Grade 1B).

**Perioperative hemodynamics: fluid management, vasopressors, and allogenic blood transfusions**

Perioperative hemodynamics is more relevant to microvascular breast reconstruction compared to prosthetic breast reconstruction. The goal of perioperative hemodynamic management in microvascular breast reconstruction is to maintain tissue perfusion and optimize blood flow for the flap.111 A majority of microsurgeons agree that avoiding intraoperative hypotension, often considered as a mean arterial pressure (MAP) of <65 mmHg, is critical to flap success and prefer some combination of intravenous fluids, blood products, and vasopressors to achieve this.112 Our understanding of fluid management has evolved recently, and most ERAS protocols advocate for either a balanced fluid approach (emphasizing euvoolemia, minimal weight changes, and maintenance of
normal physiology and homeostasis) or a goal-directed fluid therapy (GDFT) (emphasizing optimal cardiac output and oxygen delivery to tissues to prevent hypoperfusion).\textsuperscript{115} In microvascular breast reconstruction, there is evidence to support a focus on maintenance of a zero, or near zero, fluid balance. Data from two retrospective studies demonstrate that excessive underresuscitation contributes to an increased risk for adverse flap events.\textsuperscript{114,115} Similarly, retrospective studies have shown liberal fluid resuscitation or fluid overload increases flap complications in both breast reconstruction and other microvascular flap procedures.\textsuperscript{115–119} In the nonfree flap population, meta-analyses of RCTs reaffirm the value of balanced fluid therapy in reducing perioperative complications and LOS.\textsuperscript{120,121} There are no studies evaluating GDFT, which uses hemodynamic monitoring to guide fluid management, in microvascular breast reconstruction. However, multiple meta-analyses on GDFT in surgical patients demonstrate reductions in complications and LOS compared to standard or liberal fluid resuscitation models.\textsuperscript{122–129} There are no studies comparing GDFT with balanced fluid therapy.

Although vasopressors were initially presumed to have devastating effects on free flap success, recent evidence has not corroborated these fears. A 2014 systematic review of retrospective studies showed no consistent effects on flap perfusion or flap complications.\textsuperscript{130} Subsequent to that publication, a retrospective cohort study of 682 patients and 1039 flaps also failed to demonstrate an increased risk of thrombotic events or flap loss in patients receiving vasopressors.\textsuperscript{131}

In contrast to vasopressors and a balanced fluid approach, there is evidence suggesting that perioperative allogenic red blood cell transfusions in microvascular breast reconstruction are associated with an increased rate of postoperative complications and additional resource utilization. Six retrospective studies, all published after 2011, concluded that perioperative transfusions increase postoperative complications, prolong LOS, and incur additional costs; therefore, restrictive transfusion strategies (avoid transfusions in patients with hemoglobin thresholds >7 g/dL) are now advocated.\textsuperscript{132–138}

Recommendation: Perioperative fluid management should follow principles of balanced fluid therapy or GDFT and avoid underresuscitation and/or fluid overload (Grade 1A). Vasopressors may be used as an adjunct to intravenous fluids to avoid intraoperative hypotension and maintain hemodynamic stability; to date, human clinical studies have not demonstrated adverse complications with vasopressor use in microvascular breast reconstruction, albeit the existing data are of low quality (Grade 2C). We recommend a restrictive strategy for allogenic transfusions to minimize postoperative complications and avoid prolonged LOS (Grade 1C).

Minimally invasive operative techniques (in autologous breast reconstruction)

Muscle-sparing procedures (donor-site)

Minimizing the invasiveness of surgical procedures is a key component of ERAS protocols in different specialties. All patients treated in the included ERAS protocols for microvascular breast reconstruction underwent either a unilateral procedure or a bilateral procedure utilizing free TRAM (FTRAM), muscle-sparing TRAM (MS-TRAM), or DIEP flaps; there were no superficial inferior epigastric artery (SIEA) flaps reported. SIEA and DIEP flaps, which theoretically preserve the abdominal wall, would constitute the spectrum of “minimally invasive” surgery when compared with FTRAM or MS-TRAM flaps or pedicled flaps in autologous breast reconstruction. In regard to acute recovery, a majority of the data compares DIEP flaps with TRAM flaps (with MS-TRAM and FTRAM often combined into one group). There are three retrospective studies demonstrating that mean LOS is shorter in patients undergoing DIEP flaps than in patients undergoing TRAM flaps.\textsuperscript{139–141} There is also a single prospective cohort study demonstrating significantly shorter LOS for SIEA flaps compared with DIEP flaps; however, this study is limited by inadequate sample size and the lack of control for comorbidities.\textsuperscript{142} In regard to long-term postoperative function, there are multiple meta-analyses of nonrandomized observational studies comparing donor-site morbidity and abdominal wall function in patients undergoing MBR with DIEP, SIEA, or TRAM flaps.\textsuperscript{143–146} These studies demonstrate that SIEA and DIEP flaps reduce donor-site morbidity, including abdominal bulge or hernia, compared to TRAM flaps but may increase the risk of flap-related complications. However, there are several methodological limitations to the studies included in these meta-analyses, which make them highly susceptible to bias. Interestingly, a recent multicenter study in North America did not find significant differences in patient-reported outcomes of abdominal well-being or morbidity when comparing DIEP flaps with TRAM flaps.\textsuperscript{147}

Recommendation: Surgeons must consider the benefits of potentially reduced abdominal wall morbidity against the potential risk of higher complications and the potential burdens of increased operative time and complexity associated with SIEA and DIEP flaps. We suggest autologous breast reconstruction be performed with DIEP flaps whenever feasible but acknowledge the decision to perform a SIEA, DIEP,
MS-TRAM, FTRAM, or pedicled autologous flap, which is most often dictated by patients’ anatomy and characteristics (Grade 2B).

Rib-sparing techniques (recipient site)
In addition to donor-site preservation, a less invasive approach to the recipient site is also advocated in the literature for microvascular breast reconstruction. The presumed benefit of a rib-sparing approach to internal mammary vessel harvest is diminished chest wall morbidity, whereas the presumed disadvantages are complexity in patients with narrow intercostal spaces and limited exposure, which may lead to operative complications.148 To date, there is low-quality evidence to support rib-sparing techniques. Seven retrospective studies have been published, most of which focus on the efficiency and safety of this technique.149–155 Due to substantial heterogeneity, comparison across studies is limited. Only three studies included a comparison group (costochondral segment removed) and two of these compared postoperative pain, both demonstrating significantly reduced pain with rib preservation.151,153,154 In regard to complications, most studies had no comparison group but reported a low incidence of complications in line with acceptable published standards for breast reconstruction; however, one study did find a significantly greater incidence of fat necrosis with a rib-sparing approach.154

Recommendation: There is low-quality evidence to support rib-sparing techniques in microvascular breast reconstruction, and substantial uncertainty is present in the estimates of benefits, risks, and burdens associated with this technique. Given this, we can only formulate a weak recommendation that surgeons perform rib-sparing techniques in patients with suitably wide intercostal spaces; however, other alternatives may be equally reasonable (Grade 2C).

Prevention of postoperative nausea and vomiting (PONV)
Avoidance of PONV is frequently identified by patients as their top priority in the immediate postoperative recovery period; therefore, the American Society of Anesthesiologists (ASA) recommends prophylaxis for PONV, in addition to minimize opiate use, in the perioperative period.156–159 There are many agents with antiemetic effects; however, the best evidence supports 5-HT3 receptor antagonists (eg, ondansetron), dexamethasone, and transdermal scopolamine. Data from recent meta-analyses indicate that 5-HT3 receptor antagonists, dexamethasone, and scopolamine are independently effective at reducing PONV and the need for rescue antiemetics when administered prophylactically.159–161 There are also several RCTs, comparing combination prophylaxis with multiple agents versus single-agent prophylaxis that demonstrate a benefit to combination therapy; however, various combinations used and differences in patient populations precluded pooled analyses.159,162–166

Recommendation: We recommend pharmacological prophylaxis with a combination of antiemetic agents to prevent PONV and limit the need for rescue treatment (Grade 1A).

Postoperative management
Postoperative analgesia
Minimizing the opiate use is an essential goal in any ERAS protocol. There is considerable support in the literature for incorporating NSAIDs, including intravenous ketorolac, into multimodal analgesia protocols. A Cochrane review of 72 RCTs demonstrated that NSAIDs significantly reduce postoperative pain compared to placebo.167 Data from three other meta-analyses also confirm NSAIDs, as a part of multimodal therapy, reduce postoperative pain, and minimize some adverse effects, including PONV, of opiates in the postoperative period.168–170 In regard to ketorolac, a meta-analysis of 13 RCTs in a diverse group of surgical patients found that ketorolac significantly reduced postoperative pain, opioid consumption, and PONV.171 Recently, Afonso et al63 demonstrated that the addition of intravenous ketorolac to liposomal bupivacaine TAP blocks significantly reduced opioid consumption compared to TAP blocks alone in patients undergoing microvascular breast reconstruction. These findings support a prior retrospective cohort study that found ketorolac, as an adjunct treatment, reducing opiate use in TRAM flap breast reconstruction.172 Additionally, bleeding concerns with the use of ketorolac are not substantiated by the literature, for either breast reconstruction or surgical procedures in general.63,170,172,173

In addition to NSAIDs, acetaminophen has been suggested as an adjunct to perioperative pain management protocols in breast reconstruction. A Cochrane review of 51 RCTs demonstrated that acetaminophen use, compared to placebo, significantly reduced postoperative pain in surgical patients.174 Furthermore, a recent systematic review concluded that a combination of acetaminophen and NSAIDs offers superior analgesia when compared with either drug alone, lending additional support to the concept of multimodal analgesia protocols.175

Similar to NSAIDs and acetaminophen, gabapentin is frequently included in ERAS protocols, with the presumed benefit being the inhibition of nociception and central
sensitization. There are no studies evaluating the independent effect of gabapentin on postoperative pain in breast reconstruction; however, multiple meta-analyses indicate that gabapentin has both a significant analgesic and an opioid sparing effect in surgical patients.

Recommendation: Minimizing the opiate use and postoperative pain is an essential goal of multimodal perioperative care protocols. While minimal direct evidence exists in breast reconstruction, sufficient high-quality evidence may be extrapolated to support the inclusion of NSAIDs (ie, ketorolac), acetaminophen, and gabapentin in ERAS protocols to reduce postoperative pain and opiate use (Grade 1A).

Early ambulation and functional recovery
All of the ERAS protocols included ambulation as a criterion for discharge, with early mobilization at postoperative day (POD) 1 emphasized. There are no studies that evaluate the independent impact of early ambulation on postoperative outcomes in breast reconstruction and limited studies in the broader surgical literature. A recent systematic review concluded that there may be some benefit to accelerate bowel function and reduce hospital LOS with early mobilization in the abdominal and thoracic surgical populations; however, the poor methodological quality of included studies and inconsistencies in reporting of outcomes made it difficult to draw any firm conclusions. The primary proposed benefit for early mobilization is the absence of prolonged immobilization, which is known to be associated with adverse events, including venous thromboembolism, pulmonary deconditioning, and muscle weakness. The risks of early ambulation are unclear. If patients avoid significant flexion/extension at the waist, it is hard to identify a theoretical premise for how early ambulation would potentiate flap or donor-site complications in abdominally based autologous breast reconstruction. Furthermore, the only burden of early mobilization is the requirement for physical therapy or nursing assistance until patients can ambulate independently; however, this requirement is likely present regardless of the date of ambulation.

Recommendation: We recommend early ambulation be included in ERAS protocols for breast reconstruction. While there is a lack of high-quality evidence, the potential benefits appear to outweigh the risks and burdens for early mobilization (Grade 1C).

Timing of urinary catheter removal
Urinary catheter placement is significantly more common for lengthy autologous breast reconstruction procedures compared to prosthetic procedures. In microvascular breast reconstruction, all patients typically require urinary catheterization, given the length of surgery and need for resuscitative monitoring. The timing of catheter removal was a focus in the published ERAS protocols for microvascular breast reconstruction, with all including removal of urinary catheters at POD 1 as a protocol item. There is high-quality evidence, including meta-analyses and RCTs, from the nonmicrovascular surgical literature to support this practice. In general, these studies have found lower rates of catheter-associated urinary tract infections and no significantly increased risk of recatheterization in patients who had early (POD 1) catheter removal.

Recommendation: We recommend the removal of urinary catheters by POD 1, at the latest, in all patients undergoing breast reconstruction who do not require resuscitative monitoring (Grade 1A).

Timing of postoperative nutrition
Similar to the concepts of early mobilization and early removal of urinary catheters, surgeons in various disciplines have recommended early postoperative oral feeding (within 24 hours of surgery) to enhance recovery by facilitating return to normal functioning. Traditionally, patients undergoing prosthetic breast reconstruction were advanced to clear liquids and then a regular diet as tolerated immediately after surgery whereas patients undergoing microvascular breast reconstruction were kept NPO for at least 24 hours as a precaution in case where emergent return to the operating room was necessary. As detailed earlier, fasting from oral liquids does not alter anesthetic risks. Furthermore, given the low rate of flap complications requiring immediate take back, this practice of delayed oral intake is unnecessary. Although no direct evidence exists in breast reconstruction, there is considerable evidence from the broader surgical literature that early postoperative oral feeding is beneficial. Two recent meta-analyses, a 2014 Cochrane review of RCTs in abdominal gynecological surgery and a 2016 meta-analysis of 15 studies in gastrointestinal surgery, showed that early feeding was associated with shorter LOS, higher satisfaction, and no increase in complications when compared with traditional timing.

Recommendation: For prosthetic reconstruction, we recommend advancing patients’ diets as tolerated on POD 0. For microvascular breast reconstruction, we recommend postoperative oral feeding with clear liquids commencing immediately postoperatively (POD 0), with intake guided by
patient preference and comfort. In patients tolerating clear liquid intake, we advocate advancement to a regular diet on POD 1 (Grade 1B).

Discussion and future directions

Increasing health care costs have led to significant health care reforms and the advent of value-based and alternative payment models that incentivize value, efficiency, and quality in patient care.\textsuperscript{22,188} In these new paradigms, it is critical to provide high-quality care while minimizing resource utilization during an episode of care. In response, ERAS protocols have been proposed as potential strategies to improve the overall value of surgical care. While widely utilized in various surgical disciplines, few studies have evaluated ERAS protocols in breast reconstruction.\textsuperscript{64} In this study, we comprehensively reviewed the literature on ERAS protocols for breast reconstruction and provided evidence-based recommendations for each perioperative intervention included in these protocols.

Although it is promising to start to find ERAS protocols utilized in breast reconstruction, there remains a paucity of high-quality evidence on the impact of these protocols. To date, only five retrospective studies have been published on ERAS protocols in breast reconstruction and there is a significant heterogeneity between these studies in regard to perioperative interventions included, patient groups, comorbidities reported, and outcomes measured. There is a substantial need for additional research endeavors on this topic. It is important that future efforts to develop and implement ERAS protocols in breast reconstruction follow evidence-based guidelines in development and clearly report the components of the protocol. Future RCTs or high-quality prospective cohort studies are a priority. For studies following a nonrandomized observational design, patient and treatment covariates should be reported and controlled for analytically. Furthermore, studies should report clinically meaningful outcomes in a standardized way to facilitate comparison. All studies should, at minimum, report LOS, postoperative opiate use, and patient-reported outcomes using validated measures, including QoR and health-related quality of life (BREAST-Q). Additionally, studies examining the cost-effectiveness of ERAS protocols in breast reconstruction are needed to demonstrate if this intervention has value to the health care system. Finally, it would be valuable for studies to identify barriers and enablers to protocol implementation and provide a detailed description of the implementation process. Understanding these elements would allow different institutions to adapt evidence-based protocols to their local environment.

Conclusion

Optimizing the perioperative management of patients undergoing microvascular breast reconstruction by implementing ERAS protocols has the potential to improve postoperative pain control, enhance patient-centered outcomes, accelerate recovery, and minimize health care resource utilization. Institutions and surgeons aiming to optimize perioperative care in MBR should incorporate evidence-based interventions in the development of future ERAS protocols. Ultimately, following evidence-based recommendations, as delineated in this study, is integral to develop and implement treatment protocols with external validity that improve the quality and value of patient care.

Acknowledgments

RPP is supported by a National Institutes of Health (NIH) Ruth L Kirschstein National Research Service Award Institutional Research Training Grant (T32CA190194), the Foundation for Barnes-Jewish Hospital, and a National Cancer Institute Cancer Center Support Grant to Siteman Cancer Center (P30 CA091842). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.

Disclosure

The authors report no conflicts of interest in this work.

References


79. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists task force on preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration. *Anesthesiology.* 2017;126(3):376–393.


106. Webster J; Osborne S. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev. 2015;2:CD004985.


117. Clark JR; McCluskey SA; Hall F; et al. Predictors of morbidity following free flap reconstruction for cancer of the head and neck. Head Neck. 2007;29(12):1090–1101.


